Please try another search
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CS-2023 to treat meningitis; CS-2028 for treating multivalent conjugate vaccine; CS-2032 for hingles; CS-2036 to treat polio; CS-2047 for treating tetanus; and CS-2201 DTcP for combination vaccine. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People’s Republic of China.
Name | Age | Since | Title |
---|---|---|---|
David Briles | - | - | Member of Scientific Advisory Board |
Liang Lin | 49 | 2013 | Non-Executive Director |
Wing Yu Leung | 53 | 2015 | Non-Executive Director |
Shiu Kwan Wai | 59 | 2018 | Independent Non-Executive Director |
Jing Wang | 42 | 2017 | Chief Commercial Officer, Deputy GM & Executive Director |
Yingyu Liang | 52 | - | Non-Executive Director |
Shan Lu | - | 2022 | Member of the Scientific Advisory Board |
David Salisbury | - | 2023 | Member of Scientific Advisory Board |
Yingyu Liang | 52 | - | Non-Executive Director |
Shiu Kwan Wai | 59 | 2018 | Independent Non-Executive Director |
Jingren Zhang | - | - | Member of Scientific Advisory Board |
Pierre Van Damme | - | 2023 | Member of Scientific Advisory Board |
Xuefeng Yu | 59 | 2009 | Co-Founder, Executive Chairman, CEO & GM |
Dongxu Qiu | 63 | 2009 | Co-Founder, Executive VP, Deputy GM & Executive Director |
Tao Zhu | 50 | 2009 | Co-Founder, Deputy GM, Chief Scientific Officer & Executive Director |
Shou-Bai Chao | 60 | 2018 | COO, Deputy GM & Executive Director |
Wing-Yu Leung | 53 | - | Non-Executive Director |
Wing-Yu Leung | 53 | - | Non-Executive Director |
Wing-Yu Leung | 53 | - | Non-Executive Director |
Jianzhong Liu | 59 | 2019 | Independent Non-Executive Director |
Zhu Xin | 55 | 2018 | Independent Non-Executive Director |
Zhi Xiao | 46 | 2019 | Chairman of Employee Representative Supervisor |
Luis Barreto | 71 | 2018 | Member of Scientific Advisory Board |
Shuifa Gui | 59 | 2019 | Independent Non-Executive Director |
George R. Siber | 79 | 2023 | Co-Chair of Scientific Advisory Board |
Leung Cheung Yiu | - | - | Independent Non-Executive Director |
Liming Li | - | 2023 | Co-Chair of Scientific Advisory Board |
Wing-Yu Leung | 53 | - | Non-Executive Director |
Wing-Yu Leung | 53 | - | Non-Executive Director |
Wing-Yu Leung | 53 | - | Non-Executive Director |
Zhongqi Shao | 63 | 2021 | Supervisor |
Yuan Zhou | 36 | 2023 | Employee Representative Supervisor |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review